Join us at BioSpain 2016 in Bilbao, September 28th – 30th.
If you want to find out more about what we do and are a potential Investor or Partner, please contact us through the BioSpain Partnering platform or by email to noccleston@
Atlas Molecular Pharma will be attending BioSpain 2016 in Bilbao, September 28th – 30th
Related Posts
-
Atlas Molecular Pharma recibe la aprobación de la Administración de Drogas y Alimentos de los Estados Unidos de un medicamento huérfano para el tratamiento de la porfiria eritropoyética congénita GalleryAtlas Molecular Pharma recibe la aprobación de la Administración de Drogas y Alimentos de los Estados Unidos de un medicamento huérfano para el tratamiento de la porfiria eritropoyética congénita
-
Atlas Molecular Pharma receives approval by the US Food & Drug Administration of an Orphan Drug for the treatment of Congenital Erythropoietic Porphyria Gallery
Atlas Molecular Pharma receives approval by the US Food & Drug Administration of an Orphan Drug for the treatment of Congenital Erythropoietic Porphyria
-
ATLAS Molecular Pharma awarded with the research grant ‘Cristina Pericàs Almendro’ 2018-2019 by the Spanish Association for Creutzfeldt-Jakob disease GalleryATLAS Molecular Pharma awarded with the research grant ‘Cristina Pericàs Almendro’ 2018-2019 by the Spanish Association for Creutzfeldt-Jakob disease
-
Atlas Molecular Pharma recibe la aprobación de la Comisión Europea de un medicamento huérfano para el tratamiento de la Porfiria Eritropoyética Congénita GalleryAtlas Molecular Pharma recibe la aprobación de la Comisión Europea de un medicamento huérfano para el tratamiento de la Porfiria Eritropoyética Congénita
-
Atlas Molecular Pharma receives approval by the European Commission of an Orphan Medicinal Product for the treatment of Congenital Erythropoietic Porphyria Gallery
Atlas Molecular Pharma receives approval by the European Commission of an Orphan Medicinal Product for the treatment of Congenital Erythropoietic Porphyria